Blog

Many real estate experts believe that iBuying -- the business of buying homes directly from homeowners and selling directly to buyers -- has massive growth potential. But no company has figured out

It has been a stunning rise for Sea Limited (NYSE: SE), the emerging gaming, e-commerce, and digital finance giant based in Singapore. Just how stunning? Well, shares went public on the New York

Large British banks have not seen much love from investors since the Great Recession. Brexit and very low interest rates have not helped. The largest banks headquartered in the United Kingdom all

You might not immediately think of Abbott Laboratories (NYSE: ABT) as a coronavirus stock. The company is well diversified -- with medical devices, diagnostics, nutrition, and pharmaceutical

Social Security benefits don't provide as much money as many people think. In fact, the average retiree receives just $1,544 per month in 2021. That's hardly enough to live on. 

The good news is

International Business Machines (NYSE: IBM) continues to transform itself into more of a cloud company. It has increasingly stood out as a hybrid cloud leader since acquiring Red Hat in 2019

A once-a-century pandemic has created a tough task for management teams trying to forecast the future. A wave of COVID-19 can shut down businesses, ramp up online commerce, and generally upend any

When I first noticed Cassava Sciences (NASDAQ: SAVA) in July, the stock had already gone up by more than 1,000% over six months, from $7 per share to $90. What does that dramatic price shift say to

Fintech giant Square (NYSE: SQ) has several different ways it generates revenue, and many investors don't really understand how much comes from each source. In this Fool Live video clip, recorded on

Longtime Fool.com contributors Matt Frankel, CFP, and Jason Hall compared some of their portfolios' most beaten-down stocks on an episode of The Rank, recorded on Aug. 23. The worst performer in

Biotech specialist Exelixis (NASDAQ: EXEL) has had a rough year in the stock market. On June 28, the company's shares dropped by more than 20% on the heels of unimpressive results from a clinical

As the proverb goes, talent hits targets that nobody else can hit, but genius hits targets that nobody else can see. If you want your portfolio to outperform, sometimes it's necessary to look for

To say that Moderna (NASDAQ: MRNA) and BioNTech (NASDAQ: BNTX) investors have had a great year would be an understatement. The two stocks have gained around 265% and 340%, respectively, year to

Most of the headlines over the past two years about Pfizer (NYSE: PFE) have involved its vaccine for COVID-19. That makes sense. We have been in the middle of a pandemic. But the picture is clearing

Axonics (NASDAQ: AXNX) specializes in making medical devices to treat bladder and bowel dysfunction. It's the type of therapy that may be embarrassing to some, but the company's financial

After the reaction to its recent second-quarter earnings report, a $1 trillion market cap is probably the last thing on the minds of Roku (NASDAQ: ROKU) investors. The stock began to drop after the

There's a very good chance that legal cannabis could be one of the decade's most impressive growth trends.

According to New Frontier Data, the U.S. weed market is on track to grow by an annualized

There are plenty of biotech stocks that are expensive. Their valuations depend on highly risky pipeline candidates achieving success. But not every biotech stock is priced at a premium.

We asked

If youʻre an income investor, you want a stock with a strong dividend yield -- that is, the amount of its cash payouts as a percentage of its share price. The average dividend yield is south of 2%

When most of us think of successful coronavirus stocks, we think of vaccine makers. But treatment makers are gaining momentum these days -- and that movement may not be over. Why? Coronavirus cases

Some stocks might seem too big to generate explosive growth. Others could be so small that their risk level isn't appealing. However, similar to the old story of Goldilocks and the three bears

For the past 12 years, growth stocks have rightly been the talk of Wall Street. Precipitously declining interest rates and abundant access to cheap capital have allowed fast-paced companies to

Many people dream of retiring with $1 million or more to their name. Now the reality is that you don't really have to fixate on a $1 million nest egg. You may be able to do just fine in retirement

Each year, the Social Security Trustees release a report outlining the state of the program's finances. This year's report was delayed by many months, but it was finally released at the end of

Image source: The Motley Fool.

 (NYSE: AI)Q1 2022 Earnings CallSep 01, 2021, 5:00 p.m. ET

Operator

Continue reading

Source Fool.com